Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Non-Current Liabilities (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Other Non-Current Liabilities data on record, last reported at $43.9 million in Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 612.64% year-over-year to $43.9 million; the TTM value through Dec 2025 reached $43.9 million, up 612.64%, while the annual FY2025 figure was $43.9 million, 612.64% up from the prior year.
  • Other Non-Current Liabilities reached $43.9 million in Q4 2025 per LCTX's latest filing, up from $18.8 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $43.9 million in Q4 2025 and bottomed at $1000.0 in Q2 2023.
  • Average Other Non-Current Liabilities over 5 years is $6.9 million, with a median of $22000.0 recorded in 2021.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 98.8% in 2022, then surged 612.64% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $39000.0 in 2021, then tumbled by 94.87% to $2000.0 in 2022, then tumbled by 50.0% to $1000.0 in 2023, then surged by 616000.0% to $6.2 million in 2024, then soared by 612.64% to $43.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $43.9 million in Q4 2025, $18.8 million in Q2 2025, and $6.2 million in Q4 2024.